Epidemiology and outcome of Rhodotorula infection in haematological patients

Mycoses

Volumn 54, Issue 4, 2011, Pages 318-324

  Garcia Suarez J ^a   Gomez Herruz P ^b   Cuadros, J A ^b   Burgaleta, C ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

Author keywords

Central venous catheter; Fungaemia; Haematological diseases; Rhodotorula

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; VORICONAZOLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE LEUKEMIA; CATHETER INFECTION; CATHETER REMOVAL; CENTRAL VENOUS CATHETER; CHRONIC DISEASE; DISEASE PREDISPOSITION; FUNGEMIA; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; MORTALITY; MYCOSIS; NEUTROPENIA; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; RHODOTORULA GLUTINIS; RHODOTORULA INFECTION; RHODOTORULA MUCILAGINOSA; RISK FACTOR; SOLID TUMOR; SYSTEMATIC REVIEW;

HEMATOLOGIC NEOPLASMS; HUMANS; INTENSIVE CARE; MYCOSES; RHODOTORULA; RISK FACTORS; SEPSIS; TREATMENT OUTCOME;

RHODOTORULA MUCILAGINOSA;

EID: 79959265851     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2010.01868.x     Document Type: Review

References (37)

1. Fell JW, Boekhout T, Fonseca A, Scorzetti G, Statzell-Tallman A. Biodiversity and systematics of basidiomycetous yeasts as determined by large-subunit rDNA D1/D2 domain sequence analysis. Int J Syst Evol Microbiol 2000; 50: 1351-71.
2. Vartivarian SE, Anaissie EJ, Bodey GP. Emerging fungal pathogens in immunocompromised patients: classification, diagnosis, and management. Clin Infect Dis 1993; 17(Suppl. 2): S487-91.
3. Tuon FF, Costa SF. Rhodotorula infection. A systematic review of 128 cases from literature. Rev Iberoam Micol 2008; 25: 135-40.
4. Tuon FF, de Almeida GM, Costa SF. Central venous catheter-associated fungemia due to Rhodotorula spp. A systematic review. Med Mycol 2007; 45: 441-7.
5. Krcmery V, Krupova I, Denning DW. Invasive yeast infections other than Candida spp. in acute leukaemia. J Hosp Infect 1999; 41: 181-94.
6. Costa SF, Marinho I, Araújo EA, Manrique AE, Medeiros EA, Levin AS. Nosocomial fungaemia: a 2-year prospective study. J Hosp Infect 2000; 45: 69-72.
7. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988; 16: 128-40.
8. Kiehn TE, Gorey E, Brown AE, Edwards FF, Armstrong D. Sepsis due to Rhodotorula related to use of indwelling central venous catheters. Clin Infect Dis 1992; 14: 841-6.
9. Anaissie E, Bodey GP, Kantarjian H et al. New spectrum of fungal infections in patients with cancer. Rev Infect Dis 1989; 11: 369-78.
10. Sheu MJ, Wang CC, Wang CC, Shi WJ, Chu ML. Rhodotorula septicemia: report of a case. J Formos Med Assoc 1994; 93: 645-7.
11. Colombo AL, Dantas LS, Abramczyk ML et al. Rhodotorula glutinis Fungemia: a case report and literature review. Braz J Infect Dis 1997; 1: 204-7.
12. Fanci R, Pecile P, Martinez RL, Fabbri A, Nicoletti P. Amphotericin B treatment of fungemia due to unusual pathogens in neutropenic patients: report of two cases. J Chemother 1997; 9: 427-30.
13. Kiraz N, Gülbas Z, Akgün Y. Case report. Rhodotorula rubra fungaemia due to use of indwelling venous catheters. Mycoses 2000; 43: 209-10.
14. Alliot C, Desablens B, Garidi R, Tabuteau S. Opportunistic infection with Rhodotorula in cancer patients treated by chemotherapy: two case reports. Clin Oncol (R Coll Radiol) 2000; 12: 115-7.
15. Petrocheilou-Paschou V, Prifti H, Kostis E, Papadimitriou C, Dimopoulos MA, Stamatelopoulos S. Rhodotorula septicemia: case report and minireview. Clin Microbiol Infect 2001; 7: 100-2.
16. Chung JW, Kim BN, Kim YS. Central venous catheter-related Rhodotorula rubra fungemia. J Infect Chemother 2002; 8: 109-10.
17. Zaas AK, Boyce M, Schell W, Lodge BA, Miller JL, Perfect JR. Risk of fungemia due to Rhodotorula and antifungal susceptibility testing of Rhodotorula isolates. J Clin Microbiol 2003; 41: 5233-5.
18. Pasqualotto GC, Copetti FA, Meneses CF, Machado AR, Brunetto AL. Infection by Rhodotorula spp. in children receiving treatment for malignant diseases. J Pediatr Hematol Oncol 2005; 27: 232-3.
19. Lunardi LW, Aquino VR, Zimerman RA, Goldani LZ. Epidemiology and outcome of Rhodotorula fungemia in a tertiary care hospital. Clin Infect Dis 2006; 43: e60-3.
20. Neofytos D, Horn D, De Simone JA Jr. Rhodotorula mucilaginosa catheter-related fungemia in a patient with sickle cell disease: case presentation and literature review. South Med J 2007; 100: 198-200.
21. Rodriguez-Abreu D, Bordoni A, Zucca E. Epidemiology of hematological malignancies. Ann Oncol 2007; 18(Suppl. 1): i3-i8.
22. Anaissie EJ, Kontoyiannis DP, O'Brien S et al. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med 1998; 129: 559-66.
23. Thomas X. Chemotherapy of acute leukemia in adults. Expert Opin Pharmacother 2009; 10: 221-37.
24. Auberger J, Lass-Flörl C, Ulmer H et al. Significant alterations in the epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies. Int J Hematol 2008; 88: 508-15.
25. Martino R, Subirà M. Invasive fungal infections in hematology: new trends. Ann Hematol 2002; 81: 233-43.
26. Hazen KC. New and emerging yeast pathogens. Clin Microbiol Rev 1995; 8: 462-78.
27. Gomez-Lopez A, Mellado E, Rodriguez-Tudela JL, Cuenca-Estrella M. Susceptibility profile of 29 clinical isolates of Rhodotorula spp. and literature review. J Antimicrob Chemother 2005; 55: 312-6.
28. Galán-Sánchez F, García-Martos P, Rodríguez-Ramos C, Marín-Casanova P, Mira-Gutiérrez J. Microbiological characteristics and susceptibility patterns of strains of Rhodotorula isolated from clinical samples. Mycopathologia 1999; 145: 109-12.
29. Espinel-Ingroff A. In vitro activity of the new triazole voriconazole (UK-109, 496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J Clin Microbiol 1998; 36: 198-202.
30. Pfaller MA, Diekema DJ, Gibbs DL et al. Global Antifungal Surveillance Group. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 2009; 47: 117-23.
31. Diekema DJ, Petroelje B, Messer SA, Hollis RJ, Pfaller MA. Activities of available and investigational antifungal agents against rhodotorula species. J Clin Microbiol 2005; 43: 476-8.
32. García-Suárez J, Krsnik I, Reyes E et al. Elderly haematological patients with chemotherapy-induced febrile neutropenia have similar rates of infection and outcome to younger adults: a prospective study of risk-adapted therapy. Br J Haematol 2003; 120: 209-16.
33. O'Brien SN, Blijlevens NM, Mahfouz TH, Anaissie EJ. Infections in patients with hematological cancer: recent developments. Hematology Am Soc Hematol Educ Program 2003; 438-72.
34. Cornely OA, Böhme A, Reichert D, Reuter S et al. Risk factors for breakthrough invasive fungal infection during secondary prophylaxis. J Antimicrob Chemother 2008; 61: 939-46.
35. Levenga TH, Timmer-Bonte JN. Review of the value of colony stimulating factors for prophylaxis of febrile neutropenic episodes in adult patients treated for haematological malignancies. Br J Haematol 2007; 138: 146-52.
36. Pettengell R, Bosly A, Szucs TD et al. Impact of Neutropenia in Chemotherapy-European Study Group (INC-EU). Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study. Br J Haematol 2009; 144: 677-85.
37. Anatoliotaki M, Mantadakis E, Galanakis E, Samonis G. Rhodotorula species fungemia: a threat to the immunocompromised host. Clin Lab 2003; 49: 49-55.